Key result
Metformin therapy added to a hypocaloric diet significantly improved cardiac performance, reducing the myocardial performance index to 0.38 compared to 0.49 with placebo in obese pre-diabetic patients.
Why the study?
Does metformin added to a hypocaloric diet improve inflammatory markers and cardiac performance in obese pre-diabetic patients?
Population
58 obese patients enrolled for abdominoplastic surgery, including 40 with pre-diabetes and 18…
Comparison
Metformin 850 mg oral twice a day added to a… vs Matching placebo added to a hypocaloric diet for…
Design
RCT, Randomly assigned / randomly divided in two groups, Placebo-controlled…
Follow-up
12 months
Authors
Loading...
Supports metformin addition to diet for cardiac gains in obese prediabetes; extends its role beyond glycemic control.
RCT (n=58)
Placebo-controlled
Randomly assigned
No
Does metformin added to a hypocaloric diet improve inflammatory markers and cardiac performance in obese pre-diabetic patients?
Absolute Event Rate: 0.38% vs 0.49%
p-value: p=<0.05
In obese pre-diabetic patients, adding metformin to a hypocaloric diet reduces systemic inflammation and improves echocardiographic markers of cardiac performance and hypertrophy.
Sardu et al. (2018) conducted an RCT in Obesity with pre-diabetes (n=58). Metformin vs. Placebo was evaluated on Myocardial Performance Index (MPI) at 12 months (p=<0.05). Metformin therapy added to a hypocaloric diet significantly improved cardiac performance, reducing the myocardial performance index to 0.38 compared to 0.49 with placebo in obese pre-diabetic patients.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: